Name | mizagliflozin |
---|---|
Synonyms |
mizagliflozin
KGA-3235 DSP-3235 Propanamide, 3-[[3-[4-[[3-(β-D-glucopyranosyloxy)-5-(1-methylethyl)-1H-pyrazol-4-yl]methyl]-3-methylphenoxy]propyl]amino]-2,2-dimethyl- 3-{[3-(4-{[3-(β-D-Glucopyranosyloxy)-5-isopropyl-1H-pyrazol-4-yl]methyl}-3-methylphenoxy)propyl]amino}-2,2-dimethylpropanamide 1X96A704XV 10245 GSK-1614235 |
Description | Mizagliflozin (DSP-3235, KGA-3235, GSK-1614235) is a potent, selective, orally active SGLT1 inhibitor with Ki of 27 nM, displays >350-fold selectivity over SGLT2; increases stool frequency and loosens stool consistency in phase I study; increases fecal wet weight in a dog model of loperamide-induced constipation and a rat model of low-fiber-diet-induced constipation, similar to lubiprostone. Diabetes Phase 1 Clinical |
---|---|
References | References 1. Inoue T, et al. Eur J Pharmacol. 2017 Jul 5;806:25-31. View Related Products by Target SGLT Diabetes |
Density | 1.3±0.1 g/cm3 |
---|---|
Boiling Point | 837.0±65.0 °C at 760 mmHg |
Molecular Formula | C28H44N4O8 |
Molecular Weight | 564.671 |
Flash Point | 460.0±34.3 °C |
Exact Mass | 564.315918 |
LogP | 0.59 |
Vapour Pressure | 0.0±3.2 mmHg at 25°C |
Index of Refraction | 1.588 |
Storage condition | 2-8°C |